<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05044533</url>
  </required_header>
  <id_info>
    <org_study_id>CV185-770</org_study_id>
    <nct_id>NCT05044533</nct_id>
  </id_info>
  <brief_title>A Study Evaluating Quality of Life for Participants With Atrial Fibrillation (AF) Following a Bleed (EQUAL-AF)</brief_title>
  <acronym>EQUAL-AF</acronym>
  <official_title>Evaluating QUAlity of Life of AF Patients Following a Bleed (EQUAL-AF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this observational study is to identify participants with both minor and major&#xD;
      bleeds as a result of anticoagulant treatment for AF and evaluating their QoL through both&#xD;
      primary and secondary care settings.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 31, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Distribution of characteristics of AF participants: Quality of life (QoL) data</measure>
    <time_frame>Up to 90 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of characteristics of AF participants: Impact of the anticoagulation treatment</measure>
    <time_frame>Up to 90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Distribution of outcomes of AF participants: Timing of bleeding occurrence</measure>
    <time_frame>Up to 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of outcomes of AF participants: Nature of the bleed</measure>
    <time_frame>Up to 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of outcomes of AF participants: Current Bleeding treatment</measure>
    <time_frame>Up to 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of outcomes of AF participants: Location of bleed</measure>
    <time_frame>Up to 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of outcomes of AF participants: Documented cause of bleed</measure>
    <time_frame>Up to 90 days</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <description>Participants with atrial fibrillation (AF) experiencing a bleed</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients (â‰¥18) who have Atrial fibrillation (AF) and are actively prescribed oral&#xD;
        anticoagulant therapies (OATs) and have recently experienced bleeds, up to a maximum of 30&#xD;
        days prior to enrolment. No upper age limit will be applied, but patients must match all&#xD;
        other inclusion/exclusion criteria.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please&#xD;
        visit www.BMSStudyConnect.com&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients (&gt;= 18 years old)&#xD;
&#xD;
          -  Patients who can understand all study information and literature to provide fully&#xD;
             informed consent&#xD;
&#xD;
          -  Atrial fibrillation (AF) as the primary diagnosis&#xD;
&#xD;
          -  Having a major or minor bleed up to a maximum of 30 days prior to point of enrolment&#xD;
&#xD;
          -  Receiving oral anticoagulation therapy for AF&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Patients with active cancer&#xD;
&#xD;
          -  Patients unable to consent for themselves&#xD;
&#xD;
          -  Patient on concomitant antiplatelet therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,</last_name>
    <phone>please email:</phone>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT # and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Swansea</city>
        <zip>SA2 8PP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0001</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 10, 2021</study_first_submitted>
  <study_first_submitted_qc>September 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2021</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BMS-562247</keyword>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Oral Anticoagulant</keyword>
  <keyword>Prospective Study</keyword>
  <keyword>Quality of Life (QoL)</keyword>
  <keyword>United Kingdom</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

